Who is in
Who is in: Class IIb/III scope, expert-panel gating, and the selection criteria.
Free field guide · PDF
EU HTA & Joint Clinical Assessment2026 Field Guide
The first device JCAs: who is in, how it runs, and where it ends — with the evidence strategy you need.
- First JCAs
- 2026
- Framework
- PICO
- Report
- Not binding
Sourced from verified 2026 publications.
Download the free guide
Enter your work email and we'll send the PDF straight to your inbox.
What's inside
Five pages, zero fluff
Every figure in this guide traces to a named source — verified 2026 publications.
How it runs
How it runs: the PICO framework, JSC evidence advice, and the non-binding assessment.
Where it ends
Where it ends: national pricing and reimbursement, and the harmonised-evidence payoff.
Sources & scope
- cambridge.org, Implementing the EU HTA regulation and joint clinical assessment (Italy perspective).
- namsa.com, The Newly Applied European HTA Regulation: Implications for Medical Devices.
- pharmabiz.com, New European Union rules for health technology assessments become effective.
This guide is market-access intelligence, not regulatory or commercial advice. HTA rules, JCA schedules, and national procedures change — professional review is required before business use.
Market Access Strategy Session
EU access on your 2026 roadmap? Start with the full picture.
A Market Access Strategy Session maps your EU route — JCA readiness, evidence planning, and reimbursement sequencing.
Professional review is required before business use.
Back to ghmap.io Questions? Talk to our team